A 17-year experience of abobotulinumtoxina in cervical dystonia. 
To investigate the long-term efficacy and safety of a botulinum toxin type A (BoNT-A) for the treatment of cervical dystonia (CD).  We conducted a retrospective chart review of patients with CD treated with abobotulinumtoxinA (Dysport™ 100-800 units [U] for injection) between 1993 and 2009 at the University Hospital "La Paz" (LPUH).  Affected muscles were selected using electromyography (EMG).  Thirty-seven patients were included in the study; most were female (62%) and had idiopathic CD (60%).  Almost half (46%) of patients were diagnosed with the condition more than 10 years ago.  The most common clinical presentations of CD were rotation (46%) and laterocollis (43%).  On average, patients were treated with Dysport for 7 years (range: 1-17 years) and received 487 (range: 320 to 650) U over 15.9 (range: 1 to 40) injection cycles.  Most (97%) patients maintained a response from treatment initiation to end of evaluation period.  Overall, 70% of patients were taking concomitant oral medication.  Dysport was generally well tolerated.  Dysphagia was reported by 18.9% of patients, but this did not lead to discontinuation of Dysport treatment.  These data confirm the long-term efficacy and safety of Dysport in CD over a period of up to 17 years.